Sonnet BioTherapeutics press release (NASDAQ:SONN): Q3 GAAP EPS of -$0.13. Revenue of $36.85M (-40.6% Y/Y).
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results